Research published today in Science Advances has uncovered new insights into why the most aggressive oesophageal cancers are so difficult to treat and how the body\u2019s own defence systems are helping them to thrive.
Research led by the Nerlov Group in the MRC Molecular Haematology Unit provides the first detailed explanation of how parasite-fighting immune cells are selectively increased following infection.
Researchers at the Kennedy Institute of Rheumatology have found that physically resisting the formation of an immunological synapse actually promotes a stronger immune response. The findings could help explain how immune responses become weakened in cancer and chronic infection and inform the design of more effective vaccines.
Congratulations to Professor Paresh Vyas, who has been awarded a Discovery Research grant from Cancer Research UK to investigate cancer immunotherapies.
Iron deficiency affects more than a billion people worldwide and remains a leading cause of anaemia. Oxford researchers are uncovering how iron levels shape immunity and infection - insights that could inform safer, more effective strategies to tackle iron deficiency globally.
Researchers at the MRC Weatherall Institute of Molecular Medicine have developed the first combined human bone and bone marrow organoid platform capable of modelling long-term blood and immune cell production in a fully human 3D system.
Chromosomal instability (CIN) is a hallmark of aggressive cancers, yet the mechanisms through which it shapes tumour behaviour and clinical outcomes remain poorly defined. With new funding from Guts UK and the University of Oxford Medical Sciences Division, Dr Bruno Beernaert, postdoctoral researcher in the Department of Oncology, is tackling this challenge by developing innovative approaches to uncover the role of CIN in tumour evolution and immune evasion.
Can the immune system be trained to control HIV without continuous medication? A new Oxford-led clinical trial is exploring whether immune-based strategies could support longer-term viral control after stopping antiretroviral therapy.
A conversation with Professor Andrew McMichael, Professor Tom\u00e1\u0161 Hanke, and Dr Fon Acho about current priorities in HIV treatment and prevention.
The prospect of long-lasting drug-free remission for children and adults living with inflammatory arthritis is a step closer to becoming a reality, thanks to a new collaboration.
New research carried out by Dr Loren Kell at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) has demonstrated for the first time that rapamycin can reduce DNA damage in immune cells, a hallmark of ageing.
A new study from the Dushek and van der Merwe labs demonstrates a novel strategy to reduce dangerous off-target effects in engineered T cell therapies.
Research led by Dr Mariana Borsa at the Kennedy Institute has found that a cellular housekeeping mechanism called autophagy plays a major role in ensuring that T cells generate diverse progenies upon cell division. The findings, published in Nature Cell Biology, could help boost vaccine response in older adults.
Together with a group of Oxford researchers, Mark Coles, Professor of Immunology at the Kennedy Institute, will co-lead the Enabling Next-generation AI for a Bioscience-Led Economy (ENAIBLE) initiative.
An international study has identified a blood-based indicator of intestinal damage and inflammation that strongly predicts mortality in sick children. The new biomarker could help to identify those children at greatest risk of dying after hospitalisation in parts of the world with limited resources.
Over the past year, Professor Blagden has been filming for Cancer Detectives: Finding the Cures, a new three-part documentary series from Channel 4 which follows three scientists on the front lines of cancer research across the UK.
![\"\"](\"https://www.immunology.ox.ac.uk/news/new-research-reveals-why-some-oesophageal-cancers-are-so-hard-to-treat/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n